C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer
Open Access
- 5 January 2010
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (2) , 325-331
- https://doi.org/10.1038/sj.bjc.6605500
Abstract
Background: Methods and results: Conclusion:Keywords
This publication has 19 references indexed in Scilit:
- Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- Bevacizumab in the Treatment of Metastatic Colorectal Cancer (mCRC) in Second- and Third-Line SettingsSeminars in Oncology, 2006
- Identification of New Subunits of the Multiprotein Mammalian TRRAP/TIP60-containing Histone Acetyltransferase ComplexJournal of Biological Chemistry, 2003
- Treatment of non-small-cell lung cancer: state of the art and development of new biologic agentsOncogene, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Epidermal growth factor receptor tyrosine kinase inhibitorsCurrent Opinion in Pharmacology, 2002
- Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomasOncogene, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- p120 Acts as a Specific Coactivator for 9-cis-Retinoic Acid Receptor (RXR) on Peroxisome Proliferator-Activated Receptor- /RXR HeterodimersMolecular Endocrinology, 1999
- Letters to the EditorBritish Journal Of Neurosurgery, 1998